Phesi Global Data Analysis: Top Five Studied Disease Areas in 2022

Phesi’s global analysis of 80,917 trial records using Trial Accelerator™ reveals that breast cancer has retained its position as the most studied disease area, followed by COVID-19. Three of the top five most studied disease areas in 2022 are within oncology, with prostate cancer the third most studied disease, solid tumours fourth, and stroke fifth. Both prostate cancer and stroke enter the top five in 2022, replacing non-small cell lung cancer and multiple myeloma in 2021. Discover the implications for trial design and execution by downloading our report.

Key highlights:

• Breast cancer remains most studied disease area
• Overall trial activity sees widespread scale back
• Phase II terminations show sharp rise in past five years